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ABSTRACT: Oxidative stress occurs when physiological antioxidant systems do not manage to
counteract the excessive intracellular production of reactive oxygen species (ROS), which
accumulate leading to irreversible oxidation of DNA and other biomacromolecules, and thus to the
onset of pathological conditions. Autosomal recessive spastic ataxia of Charlevoix-Saguenay
(ARSACS) is a neurodegenerative disease characterized by autosomal recessive mutations in the
sacsin gene (SACS). It has been demonstrated that cells of ARSACS patients show bioenergetic and
mitochondrial impairment, denoted by reduced respiratory chain activities and ATP synthesis. In
order to design a suitable therapy for ARSACS, it is essential to consider that treatments need to
cross the blood−brain barrier (BBB), a specialized structure that separates the subtle environment
of the brain from blood circulation. Nanostructured lipid carriers (NLCs), constituted by a solid
lipid shell and a liquid lipid phase in the core, have been fabricated for loading hydrophobic
molecules, improving their bioavailability. Idebenone (IDE), a synthetic analogue of coenzyme Q10,
is able to inhibit lipid peroxidation and detoxify several free radicals. However, because of its poor
solubility, it requires ad hoc drug-delivery systems for enhancing its pharmacokinetic properties,
preventing undesired cytotoxicity. In this work, NLCs loaded with idebenone (IDE-NLCs) have been prepared. The nanovectors
have been physicochemically characterized, and their biological activity has been evaluated on different central nervous system cell
lines. IDE-NLCs demonstrated to be stable in water and in cell culture media, and showed a sustained drug release profile.
Interestingly, preliminary data demonstrated their ability to permeate an in vitro BBB model. Their protective antioxidant activity in
human healthy primary skin fibroblasts and their therapeutic efficacy in ARSACS-derived primary skin fibroblasts have been also
investigated, showing their potential for future development as therapeutic agents.
■ INTRODUCTION
Neurodegenerative diseases (NDs) are a group of pathologies
involving the central nervous system, primarily affecting
neurons and characterized by common features and symptoms.
They are mainly irreversible and may arise from genetic
mutations, endogenous issues, or environmental factors.1
Moreover, it is well known that misfolding of specific proteins,
oxidative injury, and mitochondrial dysfunctions are respon-
sible for the disruption of neuronal and axonal transports, and
consequent apoptotic phenomena.1 It has been demonstrated
that cells involved in these pathologies display higher
production of reactive oxygen species (ROS) with respect to
their healthy counterparts.2 Accumulation of ROS induces
oxidation of biological substrates and oxidative stress. This
phenomenon is emphasized by the abnormal functioning of
the mitochondria, where ATP production and calcium
regulation normally take place. Many neuronal groups require
high demands of ATP for axonal transport, and when
combined with mitochondrial impairment, they result in
being more sensitive to degeneration.3 High levels of oxidative
stress favor mitochondrial permeability transition, responsible
for threatening ionic homeostasis of neurons, altering their
metabolism, and contributing to cytotoxicity and necrosis/
apoptosis.1,4
Autosomal recessive spastic ataxia of the Charlevoix-
Saguenay type (ARSACS: MIM 270550) is an noncurable,
childhood-onset ND, characterized by autosomal recessive
mutations in SACS gene, encoding sacsin,5 a protein expressed
on the mitochondrial surface and involved in abnormal
bundling of neurofilaments of neuronal cells and in
mitochondrial network organization.6 Patients harboring
biallelic variants in SACS present progressive cerebellar
atrophy and damage of the peripheral nerves,7 and they also
manifest significant retinal changes and cognitive impairment.8
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Although the functional role of sacsin and the pathophysio-
logical consequences of its dysfunction have not been fully
understood, it is known that ARSACS cells show bio-energetic
and mitochondrial damage, denoted by reduced respiratory
chain activities and ATP synthesis.6 Sacsin has been revealed
to play a role in the correct localization of the mitochondria in
neurons and in normal dendritic morphology.7 It has been
demonstrated that sacsin knockdown leads to a more
interconnected mitochondrial network and to a change in
the mitochondria morphology toward a “balloon-like” shape.7
The hyperfused mitochondrial phenotype and lack of fission
seem to confirm that sacsin is essential in determining their
shape. Consequently, it has been hypothesized that loss of
sacsin alters correct neuronal development, growth, and
synaptic function.9,10
No effective therapies have been proposed for ARSACS. To
design a suitable treatment for patients, it is essential to
consider that potential drugs need to cross the blood−brain
barrier (BBB), an ultra-specialized structure that separates the
subtle environment of the brain from blood circulation.
Indeed, because of its physical features, such as lack of
fenestrations and a very low rate of pinocytosis, the passage of
the vast majority of therapeutic molecules and drugs is
blocked.11 To overcome BBB crossing difficulties, biocompat-
ible nanovectors have been developed, that are recognized by
brain cells, easily transportable in the bloodstream, and
carrying drugs for targeted delivery.4
Innovative fabrication techniques based on the use of natural
lipids, which facilitate encapsulation of hydrophobic drugs
preventing their degradation and decreasing systemic side
effects, easy to be functionalized for active targeting, and
allowing controlled drug release, have been recently intro-
duced.12 Nanostructured lipid carriers (NLCs) are constituted
by a solid lipid structure including a liquid lipid phase in the
core. This feature makes their structure less crystalline with
respect to solid lipid nanoparticles (SLNs), increasing the
amount of loadable payload and improving drug availability.13
Idebenone (IDE) is a synthetic analog of coenzyme Q10
(CoQ10).
14 Some evidences demonstrate that IDE inhibits
lipid peroxidation and detoxifies several free radicals.15 IDE is
employed in the treatment of diseases with mitochondrial
etiology, and it has been investigated for the treatment of
Friedreich’s ataxia (FA), a progressive inherited ataxia.16 IDE
(Raxone) has been approved by the European Medicine
Agency to treat visual impairment in adolescents and
adults.17,18 Despite the fact that IDE is less lipophilic than
CoQ10, it still remains poorly water-soluble; therefore, ad hoc
drug-delivery systems have been designed to improve its
pharmacokinetics, physicochemical properties, and stability,
preventing undesired cytotoxicity.19
Several studies have been performed to investigate the effect
of IDE-loaded liposomes on cell viability, as compared to the
free drug. Two research groups encapsulated IDE in
conventional liposomes and PEGylated large unilamellar
vesicles.20,21 These nanocarriers showed improved bioavail-
ability and reduced ethanol-induced damages upon admin-
istration. However, liposomal formulations displayed some
stability issues and fast clearance problems. Stancampiano et al.
proposed the quasi-emulsion solvent diffusion method to
encapsulate IDE in SLNs. They showed how IDE-loaded SLNs
displayed efficient antioxidant activity upon stress induced by
thermolysis of 2,2-azobis 2-amidopropane dihydrochloride
(APPH) and lower induced release of lactate dehydrogenase
(LDH) in primary cultures of astrocytes, as compared to free
IDE.22 However, because of lipid peroxidation, SLNs caused
increased oxidative stress directly proportional to their
concentration. Modifying the preparation procedure, Mon-
tenegro et al. demonstrated an improved ROS inhibition in
primary cultures of astrocytes.23 Permeability experiments on
an in vitro model of BBB were successfully performed.24
In this work, NLCs loaded with IDE (IDE-NLCs) have been
prepared for improving its delivery and intracellular release.
Nanovectors encapsulating IDE have been physicochemically
characterized, and their biological activity has been evaluated
in terms of cytotoxicity in different central nervous system cell
lines. IDE-NLCs demonstrated to be stable in water and in cell
culture media at different pH conditions and showed a
sustained release profile up to 72 h. Preliminary experiments
demonstrated their ability to permeate an in vitro BBB model.
Their protective antioxidant activity on human healthy primary
skin fibroblasts and their therapeutic efficacy in ARSACS-
derived primary skin fibroblasts has also been investigated. The
aim of this research is to provide a novel nanosystem able to
counteract the high levels of oxidative stress caused by
excessive ROS production in ARSACS patients, contributing to
the reduction of the symptoms associated with this pathology.
■ MATERIALS AND METHODS
Preparation and Purification. NLCs were fabricated by
high-temperature homogenization. The liquid lipid compo-
nent, 2.5 mg of oleic acid (Sigma-Aldrich), and the solid lipid
component, 27.5 mg of cetyl palmitate (Gattefosse ́ SAS), were
mixed to 4 mg of mPEG-DSPE (5000 Da; Nanocs Inc.) at 70
°C (over their melting temperature) to allow the rapid
evaporation of ethanol (used as the solvent; Sigma-Aldrich).
These materials have been chosen for their high biocompat-
ibility and being previously reported for NLC preparation.25
The lipid components were mixed with 1 mg of IDE (Sigma-
Aldrich) dissolved in 100 μL of ethanol for preparing IDE-
NLCs. Plain NLCs were prepared as control by mixing lipid
components with 100 μL of ethanol. Pluronic F-127 (Sigma-
Aldrich) at 10 mg/mL in water was added as a stabilizer (3
mL), and the emulsion was finally vortexed for 1 min and
sonicated (Thermo Fisher−Fisher Scientific FB120) for 10
min at 90% amplitude and stored at 4 °C for 30 min. NLCs
were then purified using Amicon Ultra-4 Centrifugal Filter
Units (MWCO 100 kDa; Sigma-Aldrich) by centrifuging at
8230 rpm for 40 min at 4 °C three times. The filtered pellet
was resuspended in sterile water, and the final suspension was
finally filtered using a 1.2 μm syringe filter and a 0.2 μm sterile
syringe filter (Sartorius Minisart Plus Syringe Filters) under a
biological hood. The concentration of IDE-NLCs was
determined using freeze-dried samples known amounts of
the final dispersion. For nanoparticle/cell interaction studies,
IDE-NLCs were labeled with Vybrant DiO cell-labeling
solution (Thermo Fisher). Particles (200 μL) were incubated
for 1 h at 37 °C with 5 μM dye. Successively, they were washed
three times with Amicon Ultra-4 Centrifugal Filter Units
(MWCO 100 kDa; Sigma-Aldrich). The collected final pellet
was resuspended in 200 μL of distilled sterile water.
Dynamic Light Scattering Measurement. Dynamic
light scattering (DLS; Malvern-Zetasizer Nano ZS90)
measurements were performed in order to evaluate size,
polydispersity index (PDI), and ζ-potential of IDE-NLCs.
Disposable polystyrene cuvettes (Malvern Zetasizer Nano
series) were used to measure IDE-NLC average hydrodynamic
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diameter, while disposable folded capillary cells (Malvern
Zetasizer Nano series) were used to measure ζ-potential. The
temperature was set at 25 °C and the equilibration time at 120
s. In order to assess the long-term stability of IDE-NLCs, size
and PDI measurements were performed by diluting nano-
particles in water, phosphate-buffered saline (PBS), Dulbecco’s
modified Eagle medium (DMEM), and DMEM supplemented
with 10% fetal bovine serum (FBS). Measurements have been
performed upon 24, 48, 72, 168, 336, 504, and 720 h of
incubation at 37 °C.
Transmission Electron Microscopy. High-resolution
transmission electron microscopy (TEM) was performed to
evaluate IDE-NLCs morphology. Samples were diluted and
sonicated for 5 min. A drop of the sample solution was placed
on a Cu grid, 150 mesh, coated with ultrathin amorphous
carbon film, previously plasma-treated (O2+Ar plasma, 10 W, 2
min), to remove hydrocarbon residues from carbon film
deposition. The grids were stored in air. The staining
procedure, to enhance the contrast of lipid particles, consisted
of a 30 s treatment of previously prepared sample grids with
1% uranyl acetate solution in water.
Drug Loading and Release. Samples were analyzed by
high-performance liquid chromatography (HPLC; Shimadzu
LC-20AT), with an Agilent TC C18 (150 mm × 4.6 mm
particle size of 5 μm, pore size of 170 Å) chromatographic
column and a UV detector. The mobile phase was composed
of 100% acetonitrile (for HPLC, ≥ 99.9 %, Sigma-Aldrich),
pumped in isocratic mode at a flow rate of 1 mL/min. The
absorbance peak of IDE was detected at 276 nm. IDE-NLCs
(200 μL) were frozen at −80 °C and subsequently freeze-dried
overnight. Acetonitrile (300 μL) was added to each sample and
left on a hot plate at 70 °C for 1 h. Cold sterile water (200 μL)
was added, and samples were centrifuged for 1 h at 15,000 rpm
at 4 °C, allowing the lipids to precipitate. Once collected, the
supernatant was analyzed by HPLC. A calibration curve was
obtained by dissolving pure IDE in acetonitrile. Drug loading
was calculated according to the following equation
drug loading (%)
idebenone mass in NLCs (mg)
total mass of NLCs (mg)
100= ×
(1)
Release studies were performed by dispersing IDE-NLCs in
different buffers. IDE-NLCs (2 mg) were diluted into PBS
(phosphate-buffered saline solution, without Ca2+ and Mg2+;
Sigma-Aldrich) at pH 7.4, in PBS pH 7.4 with 100 μM H2O2,
in 0.05 M phosphate buffer solution (potassium dihydrogen
phosphate) pH 4.5, or in 0.05 M phosphate buffer solution pH
4.5 with 100 μM H2O2. Samples were maintained at 37 °C
under agitation, and the concentrations of drug released were
evaluated at 4, 8, 24, and 72 h after filtration with Amicon
Ultra-4 Centrifugal Filter Unit (MWCO 100 kDa; Sigma-
Aldrich) at 8230 rpm for 40 min at 20 °C. Supernatants were
analyzed by HPLC. After the acquisition, the cumulative
percentage release was calculated.
Cell Cultures. Mouse astrocyte cells C8-D1A (ATCC
CRL-2541), mouse brain endothelial cells bEnd.3 (ATCC
CRL-2299), and human healthy and ARSACS patient’s
primary fibroblasts derived from skin punch biopsies were
cultured in DMEM high glucose (Sigma-Aldrich) supple-
mented with 10% heat-inactivated FBS (Gibco), 2 mM L-
glutamine (Gibco), 1 mM sodium pyruvate (Gibco), 100 IU/
mL of penicillin, and 100 μg/mL of streptomycin (all from
Gibco). Human fibroblasts were collected with informed
consent according to standard procedures for diagnostic skin
biopsies and treated according to the standards of good clinical
practice. Primary skin fibroblasts derived from two healthy
controls and two ARSACS patients at similar culture passages
(P5−P15) were investigated.
Human neuroblastoma cells SH-SY5Y (ATCC CRL-2266)
were cultured in a 1:1 mixture of DMEM and Ham’s F-12
nutrient mixture (Sigma-Aldrich), supplemented with 10%
heat-inactivated FBS (Gibco), 2 mM L-glutamine (Gibco), 1
mM sodium pyruvate (Gibco), 100 IU/mL of penicillin, and
100 μg/mL of streptomycin (all from Gibco). Cells were
induced to differentiate in human neuron-like cells by serum
deprivation (1% FBS; Gibco) and retinoic acid addition (10
μM; Sigma-Aldrich).26
Biocompatibility Investigation. For WST-1 assay, cells
were seeded in a 24-well cell culture plates (COSTAR) at a
density of 1.5 × 104 cells/well. After 24 h, cells were incubated
with IDE-NLC preparations at different IDE molar concen-
trations in complete DMEM without phenol red (Sigma-
Aldrich). In parallel, cells were incubated with free IDE
dissolved in ethanol and NLCs. Studies were performed at 24
and 72 h after incubation at 37 °C, 5% CO2. Dilution (1:20) of
cell proliferation reagent WST-1 (Roche) was prepared in 300
μL/well of DMEM without phenol red, and plates were
incubated at 37 °C for 30 min. Absorbance reading was
performed with a Victor X3 Multilabel Plate Reader (Perkin
Elmer), setting absorbance wavelength at 450 nm and 0.1 s
measurement time. Cells were then rinsed with PBS and frozen
at −80 °C. Frozen samples were treated to assess the
proliferation rate by Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen). Samples stocked at −80 °C were subjected to
three cycles of freeze/thaw in order to allow cell lysis and DNA
release. Meanwhile, a series of dilutions of the reagent and
buffer were prepared according to the manufacturer’s
instructions. Fluorescence was measured with Victor X3
Multilabel Plate Reader (Perkin Elmer), setting the excitation
wavelength at 485 nm, emission wavelength at 535 nm, and 0.1
s measurement time.
Nanoparticle/Cell Interactions. Cells were seeded in μ-
plate 24-well black IbiTreat (Ibidi) at a density of 2 × 104
cells/well. After 24 h, they were incubated with 300 μg/mL of
Vybrant DiO-labeled IDE-NLCs at 37 °C. At 24 and 72 h after
incubation, they were rinsed with PBS and fixed with 4%
paraformaldehyde at 4 °C for 30 min. After rinsing with PBS,
staining was performed by incubating cells with Hoechst 33342
dye (1 mg/mL, diluted 1:1000; Thermo Scientific) and
TRITC-phalloidin (2.5 μg/mL; Sigma-Aldrich) in 10% goat
serum (Euroclone) for 90 min at 37 °C. After a final rinse with
PBS, 500 μL of PBS were added and plates were stored at 4 °C
in the dark. A C2s confocal laser scanning microscopy
(CLSM) system, employing NIS-Elements software (Nikon),
was used for 2D and 3D confocal acquisitions.
A total of 2 × 104 cells/well was seeded in 24-well cell
culture plates (COSTAR). After 24 h, they were incubated
with 300 μg/mL of Vybrant DiO-labeled IDE-NLCs in
complete DMEM without phenol red (Sigma-Aldrich).
Samples were analyzed at 24, 48, and 72 h. Cells were
collected and centrifuged at 2600 rpm for 6 min. The pellet
was resuspended and transferred in Cytoflex Tubes (Bio-Rad).
FITC events were acquired using a flow cytometer (Cytoflex,
Beckman Coulter). The measurement threshold was set to 104
events/sample.
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Blood−Brain Barrier In Vitro Model. To set up the
model to assess the ability of developed nanovectors to cross
the barrier, a two-compartment system consisting of porous
scaffolds (24-well transwell inserts with pore size of 3.0 μm
diameter PET track-etched membrane; Corning) was used to
culture brain endothelial cells (bEnd.3) and astrocytes (C8-
D1A) at high confluence. The two cell lines were cultured on
opposite sides of the porous scaffold which separates the
luminal chamber (on the upper part) from the abluminal
compartment (on the lower part). C8-D1A cells were seeded
on the bottom side of the porous membrane, with a cell
density of 1 × 104 cells/cm2. After 24 h, the inserts were
flipped back up, and bEnd.3 cells were seeded on the apical
side of the membrane at 3 × 104 cells/cm.2 The luminal
compartment (top) was filled with 200 μL of complete DMEM
without phenol red, while the abluminal chamber (bottom)
was filled with 700 μL of complete DMEM without phenol
red. Cells were kept at 37 °C, 5% CO2, for five days.
The system was then characterized and exploited for
permeability studies. Bioelectrical properties of the cell bilayer
(C8-D1A and bEnd.3) were checked by measuring the
transendothelial electrical resistance (TEER), assessed with a
Millipore Millicell ERS-2 Volt-Ohmmeter. BBB integrity was
verified by measuring the permeability of FITC-dextran (70
kDa; Sigma-Aldrich) at different time points. A calibration
curve was obtained by dissolving FITC-dextran in complete
DMEM without phenol red. Samples were measured with
Victor X3 Multilabel Plate Reader (Perkin Elmer), setting the
excitation wavelength at 485 nm and emission wavelength at
535 nm, 0.1 s measurement time. Fresh medium (700 μL) was
added on the barrier abluminal compartments, and 200 μL of
200 μg/mL diluted of FITC-dextran solution was added in the
barrier luminal compartments (on top). Membranes without
cells were analyzed as a control in the same conditions.
Analyses were conducted by measuring fluorescence of
medium recovered in the abluminal space at 1, 4, 8, 24, 48,
and 72 h. Subsequently, IDE-NLC permeation experiments
were conducted. The calibration curve was performed for
Vybrant DiO-labeled IDE-NLCs in complete DMEM without
phenol red. Samples were measured with Victor X3 Multilabel
Plate Reader (Perkin Elmer), setting the excitation wavelength
at 485 nm, emission wavelength at 535 nm, and 1.0 s
Figure 1. (A) Representative TEM image of IDE-NLCs. (B) Size measurement of IDE-NLCs performed by DLS. (C) ζ-potential measurement of
IDE-NLCs. (D) Average hydrodynamic diameter measurement of IDE-NLCs performed by DLS. (E) PDI measurement of IDE-NLCs performed
by DLS. Stability measurements were performed in water, PBS, DMEM, and DMEM supplemented with 10% FBS at 37 °C.
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measurement time. Fresh medium (700 μL) was added on the
barrier abluminal compartments, and 200 μL of 500 μg/mL
Vybrant DiO-labeled IDE-NLC dispersion was added in the
barrier luminal compartments. Analyses were conducted by
measuring the fluorescence of medium recovered in the
abluminal space at 1, 4, 8, 24, 48, and 72 h. 3D confocal images
of the in vitro BBB model were acquired after 72 h of
incubation with Vybrant DiO-labeled IDE-NLCs.
Evaluation of Antioxidant Activity. The antioxidant
activity of IDE-NLCs was evaluated by flow cytometry in order
to detect cell oxidative stress through a fluorogenic probe that
enhances fluorescence upon ROS production. Cells were
seeded in a 6-well cell culture cluster COSTAR at a density of
6 × 104 cells/well. After 24 h, they were incubated in complete
DMEM without phenol red (Sigma-Aldrich) with IDE-NLCs,
free IDE, (corresponding to the concentration encapsulated in
300 μg/mL of IDE-NLCs), and plain NLCs. Studies were
performed after 72 h of incubation at 37 °C, 5% CO2. The
CellRox Green Reagent (Invitrogen) was diluted to a final
concentration of 5 μM in complete medium without phenol
red. Cells were rinsed once in PBS, and the reagent was added;
after 30 min at 37 °C, cells were trypsinized for 5 min at 37 °C,
collected, and centrifuged at 2600 rpm for 6 min. After
medium removal, the pellet was resuspended in 1 mL of PBS
and aliquoted into two Cytoflex Tubes (Bio-Rad), 500 μL
each. Concerning healthy fibroblasts, one tube was kept as the
control and the second one was treated by addition of 2.5 mM
tert-butyl hydroperoxide (TBH; Sigma-Aldrich). Data were
acquired using a flow cytometer (Cytoflex, Beckman Coulter).
The measurement threshold was set to 104 events/sample.
Two time points were considered, 30 and 60 min, after
oxidative stress induction. The percentages of ROS-positive
cells in each condition were normalized by the average of ROS-
positive cells of the corresponding controls (healthy cells at 30
min, healthy cells at 60 min, patient’s cells at 30 min and
patient’s cells at 60 min) derived from at least three
independent experiments.
Statistical Analysis. Statistical analysis was performed
using the R software. Normality of the data was checked
through the Shapiro−Wilk test, normally distributed data were
analyzed with the ANOVA test followed by the LSD post-hoc
test with Bonferroni correction and expressed as mean ±
standard deviation. Non-normally distributed data were
analyzed with the Kruskal−Wallis test followed by the
pairwise-Wilcoxon post-hoc test and expressed as median ±
confidence interval.
■ RESULTS
Preparation and Physicochemical Characterization of
IDE-NLCs. Upon fabrication of IDE-NLCs, nanovectors were
stained for TEM imaging, in order to evaluate their
morphology and size. Nanoparticles displayed good homoge-
neity (Figure 1A) and a size of approximately 150 nm. DLS
measurement was performed to evaluate IDE-NLCs colloidal
properties, such as size, PDI, and ζ-potential. The average
hydrodynamic diameter was 159.3 ± 3.4 nm, with a PDI of
0.224 ± 0.015, indicating monodisperse preparations. Figure
1B reports the intensity distribution of the homogeneous IDE-
NLCs population obtained by CONTIN analysis. The ζ-
potential resulted to be −33.5 ± 0.1 mV (Figure 1C). This
negative value is compatible with nanoparticle repulsion and
low aggregation. In order to assess the long-term stability of
the nanovectors, size (Figure 1D) and PDI (Figure 1E)
measurements were conducted upon dilution of IDE-NLCs in
different dispersants: water, PBS, DMEM, and DMEM
supplemented with 10% FBS. Preparations were incubated at
37 °C and analyzed at different time points: 24, 48, 72, 168,
336, 504, and 720 h. Results demonstrated that IDE-NLCs
show good stability at 37 °C, even after one month, and upon
dilution in all the considered solvents.
Loading and Release Studies. In order to estimate the
drug loading, lipids were dissolved and supernatants containing
the encapsulated molecule were collected and measured by
HPLC. IDE loading resulted to be 1.1 ± 0.4% w/w. After drug-
loading quantification, release studies were performed. IDE-
NLCs were diluted in different buffers, with variable pH,
corresponding to physiological conditions (pH 7.4) and
mimicking the intracellular acidic environment present in
lysosomes (pH 4.5), with and without oxidative stress (100
μM H2O2). The profiles obtained by HPLC showed a
sustained release up to 13 ± 2%, reaching a plateau after 72
h at 37 °C. No burst release was visible. It should be noted that
the release was pH- and H2O2-independent (Figure 2).
Figure 2. Cumulative release profile of IDE-NLCs in different buffers. Measurements were performed at pH 7.4, pH 4.5, pH 7.4 + H2O2, pH 4.5 +
H2O2.
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Evaluation of IDE-NLCs Cytotoxicity on Astrocytes,
Endothelial, and Differentiated Neuron-like Cells.
Evaluation of cytotoxicity was performed in vitro on different
cell lines upon incubation with IDE-NLCs for 24, 48, and 72 h.
C8-D1A mouse astrocytes, bEnd.3 mouse brain endothelial
cells, and human differentiated SH-SY5Y neuron-like cells were
chosen as they properly represent an in vitro model of the BBB
functionality.27 The cytotoxicity of IDE-NLCs was evaluated
by WST-1 and PicoGreen assays that were performed in order
to assess metabolic activity and proliferation rates of these cell
lines at 24 and 72 h after administration of nanoparticles.
Three IDE-NLCs concentrations were tested for each
treatment: 25.5, 127.5, and 446.3 μg/mL corresponding to 1,
5, and 17.5 μM of the loaded drug. The highest concentration
of IDE used in this work has been previously reported in a
study exploiting IDE-loaded SLNs,23 while the intermediate
and lower ones were chosen in order to evaluate a possible
range of cytotoxicity. In parallel, experiments were performed
Figure 3. (A) WST-1 assay performed on C8-D1A astrocytes incubated with free IDE, IDE-NLCs, and NLCs. (B) WST-1 assay performed on
bEnd.3 endothelial cells incubated with free IDE, IDE-NLCs, and NLCs. (C) WST-1 assay performed on differentiated SH-SY5Y neuron-like cells
incubated with free IDE, IDE-NLCs, and NLCs. Analyses were normalized on nontreated cells (CTRL); cells were also treated with ethanol
(ETOH, used for dissolving free idebenone). *p < 0.05, **p < 0.01, ***p < 0.001.
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incubating cells with free IDE and NLCs at the same
concentrations reported above.
As shown in Figure 3A, C8-D1A cells did not exhibit any
statistically significant reduction in viability at 24 h after the
treatment. At 72 h, NLC formulations gave rise to a slight
significant reduction of cell viability by a 20% in cells treated
with IDE-NLCs and NLCs at the highest concentration (p <
0.001). Regarding proliferation rates, they remained unaltered
at both time points (Figure S1A). In bEnd.3 cells, there were
small significant effects on the viability (Figure 3B) and on cell
proliferation (Figure S1B), being small fluctuations imputable
to technical imprecisions. In SH-SY5Y differentiated cells, both
assays showed a significant cytotoxic effect after the treatment
with free IDE at the highest concentration (p < 0.001; Figures
3C and S1C).
Evaluation of IDE-NLC Cellular Internalization. Upon
treatment with Vybrant DiO-labeled IDE-NLCs, a qualitative
assessment of IDE-NLC cellular localization was performed by
confocal imaging after 24 (Figures 4A, 5A, and 6A), 48
(Figures 4B, 5B, and 6B), and 72 h (Figures 4C, 5C, and 6C)
of incubation. Images of the single fluorescent channels, nuclei
(blue), Vybrant DiO-labeled IDE-NLCs (green), f-actin (red)
were acquired. The internalization of IDE-NLCs in C8-D1A
astrocytes was time-dependent, and the presence of the
nanoparticles in the cytoplasm, in particular, in the perinuclear
area, was detectable at 72 h after treatment (Figure 4A−C).
Figure 4. 2D CLSM images of C8-D1A astrocytes treated for (A) 24, (B) 48, and (C) 72 h with Vybrant DiO-labeled IDE-NLCs (green). Nuclei
(blue) and f-actin (red) were also stained. (D) Flow cytometry quantification of Vybrant DiO-labeled IDE-NLCs positive cells (%) after 24, 48,
and 72 h of incubation at 37 °C. (E) Representative flow cytometry plots obtained at the three time points.
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The amount of internalized nanoparticles (Vybrant DiO-
labeled IDE-NLCs) was quantified by flow cytometry,
evaluating the percentage of FITC-positive cells (Figure
4D,E). These results further confirmed confocal acquisitions.
The same experiment was performed on bEnd.3 cells (Figure
5A−C), which showed a predominant perinuclear localization
and increased uptake of nanoparticles over time (Figure 5D,E).
In differentiated neuron-like SH-SY5Y cells, IDE-NLCs uptake
was clearly detectable at 48 h (Figure 6A−C), reaching 60% of
FITC-positive cells at 72 h after the treatment (Figure 6D,E).
Also, in this case, nanoparticles localized in the cytoplasm and,
in particular, in the perinuclear area.
3D acquisitions of all the samples were performed at the
three time points (Figure S2A−C).
Evaluation of the IDE-NLC Crossing Ability on an In
Vitro BBB Model. A two-compartment model of BBB was
exploited in order to evaluate IDE-NLC permeation ability.
Porous scaffolds (3.0 μm diameter pores) were used for
creating a separation between the two compartments where
cells were cultured. In the luminal chamber (top), bEnd.3 cells
were plated, while on the opposite site of the porous scaffold
(abluminal compartment), C8-D1A astrocytes were grown.
The BBB model displayed a TEER of 95 ± 7.5 Ω·cm2, in
agreement with other results reported in the literature.28
FITC-dextran (70 kDa) permeability measurements are
Figure 5. 2D CLSM images of bEnd.3 endothelial cells treated for (A) 24, (B) 48 and (C) 72 h with Vybrant DiO-labeled IDE-NLCs (green).
Nuclei (blue) and f-actin (red) were also stained. (D) Flow cytometry quantification of Vybrant DiO-labeled IDE-NLCs positive cells (%) after 24,
48, and 72 h of incubation at 37 °C. (E) Representative flow cytometry plots obtained at the three time points.
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reported in Figure 7A. As it can be appreciated, the FITC-
dextran passage was significantly limited by the BBB with
respect to the plain porous scaffold (without cells), 10.94 μg/
mL versus 77.34 μg/mL at 72 h. In Figure 7B, the passage of
Vybrant DiO-labeled IDE-NLCs through the barrier is
displayed. The luminal compartment was treated with 500
μg/mL of Vybrant DiO-labeled nanoparticles, and a gradual
increase in IDE-NLCs passage was appreciable, reaching 98.55
μg/mL at 72 h after incubation with cells. An increase in the
amount of Vybrant DiO-labeled IDE-NLCs crossing the BBB
was detectable at each time point. Representative 3D confocal
images of cultured endothelial cells (Figure 7C, upper panels)
and astrocytes (Figure 7C, lower panels), acquired at 72 h after
incubation with Vybrant DiO-labeled IDE-NLCs (green), are
reported. Nuclei (blue), f-actin (red), and merged channels
were acquired. A lateral view of the in vitro BBB model is also
shown (Figure 7C, central panels).
Evaluation of IDE-NLC Cytocompatibility in Human
Healthy and ARSACS Patient’s Primary Skin Fibroblasts.
Cultured ARSACS patient’s primary skin fibroblasts were
compared to human healthy primary skin fibroblasts used as
control. In order to assess the amount of metabolically active
cells and their proliferation rate upon the treatment with IDE-
NLCs, free IDE and NLCs, WST-1, and PicoGreen assays
Figure 6. 2D CLSM images of differentiated SH-SY5Y neuron-like cells treated for (A) 24, (B) 48, and (C) 72 h with Vybrant DiO-labeled IDE-
NLCs (green). Nuclei (blue) and f-actin (red) were also stained. (D) Flow cytometry quantification of Vybrant DiO-labeled IDE-NLCs positive
cells (%) after 24, 48, and 72 h of incubation at 37 °C. (E) Representative flow cytometry plots obtained at the three time points.
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were performed at 24 and 72 h after administration. Figure 8A
shows the results in healthy control fibroblasts incubated with
IDE-NLCs, IDE, and NLCs, while Figure 8B reports the
viability results obtained in treated patient’s cells. As it can be
seen, after the treatment with nanoparticles, healthy fibroblasts
maintained their viability at both time points, even at the
highest concentration of IDE-NLCs. In the case of patient’s
fibroblasts, cell viability was reduced by a 20% after incubation
for 72 h with IDE-NLCs at the highest concentration (p <
0.001). Proliferation rates were also maintained in healthy
fibroblasts (Figure S3A), showing slightly more variability in
patient’s cells (Figure S3B).
Evaluation of IDE-NLCs Cellular Internalization in
Primary Skin Fibroblasts. Fibroblasts were seeded and
incubated with Vybrant DiO-labeled IDE-NLCs (green) for 24
(Figures 9A and 10A), 48 (Figures 9B and 10B), and 72 h
(Figures 9C and 10C), respectively, and internalization was
evaluated by confocal imaging and flow cytometry. Acquired
images are presented in Figure 9A−C for healthy fibroblasts
and Figure 10A−C for ARSACS fibroblasts (nuclei, blue; f-
actin, red; IDE-NLCs, green). The signal corresponding to the
fluorescent IDE-NLCs increased between 24 and 48 h, with no
significant differences between 48 and 72 h. 3D confocal
images of IDE-NLC uptake were acquired of healthy (Figure
S4A) and patient’s (Figure S4B) fibroblasts.
The amount of internalized nanoparticles (Vybrant DiO-
labeled IDE-NLCs) was quantified by flow cytometry,
evaluating the percentage of FITC-positive cells. Results are
reported in Figure 9D,E for human healthy fibroblasts
incubated with Vybrant DiO-labeled IDE-NLCs. As it can be
observed, healthy fibroblasts displayed 82% of FITC-positive
cells at 24 h after administration, reaching 88% at 72 h. Results
in ARSACS fibroblasts treated with Vybrant DiO-labeled IDE-
NLCs showed an increase in the internalization extent between
24 and 48 h after incubation, reaching 94% of FITC-positive
cells at 72 h after treatment (Figure 10D,E).
Figure 7. (A) Permeation curves of 70 kDa FITC-dextran through porous membranes with cells (red) and without cells (blue). (B) Vybrant DiO-
labeled IDE-NLCs permeation curve through porous membranes with cells (red). (C) 3D CLSM images of the in vitro BBB model after 72 h of
incubation with Vybrant DiO-labeled IDE-NLCs (green). Nuclei (blue) and f-actin (red) were also stained. In the top row, bEnd.3 cells (luminal
compartment); in the bottom row, C8-D1A astrocytes (abluminal compartment); in the middle, the lateral view of the two compartments.
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Antioxidant Activity Evaluation. In order to evaluate
IDE-NLCs antioxidant activity, cells were incubated with free
IDE (5 μM), IDE-NLCs (300 μg/mL, corresponding to 5 μM
of loaded drug), and NLCs (300 μg/mL). Analysis was
conducted 72 h after incubation, staining cells with the
CellRox Green Reagent. Healthy fibroblasts were treated with
TBH for inducing oxidative stress. The change in the
fluorescence intensity (FITC), corresponding to the ROS
levels, was assessed at 30 min and 60 min after oxidative stress
induction. As it can be seen in Figure 11 (upper panel), healthy
fibroblasts incubated with IDE-NLCs showed reduced ROS
levels, as demonstrated by the percentages of ROS-positive
cells, suggestive of a protective function of IDE. In particular,
control cells and NLC-treated cells showed similar percentages
of ROS-positive cells (102 ± 37 and 79.5 ± 24% respectively),
while cells treated with IDE and IDE-NLCs showed a
statistically significant lower level (p < 0.05) of ROS-positive
cells (5 ± 3 and 9 ± 6%, respectively). Similar results were
observed in healthy fibroblasts at 60 min, with control and
NLC-treated cells showing similar ROS-positive values (103 ±
40 and 60 ± 15%) and cells treated with IDE and IDE-NLCs
showing statistically significant lower values (p < 0.05) of ROS-
positive cells (8 ± 7 and 3 ± 3% respectively). The treatment
with TBH caused an increment in ROS-positive cells in all
experimental conditions; however, while control and NLC-
treated cells showed similar ROS-positive values after the pro-
oxidative stimulus at both time points (796 ± 210% for control
at 30 min, 788 ± 105% for NLCs at 30 min, 1103 ± 449% for
control at 60 min, and 1281 ± 331% for NLCs at 60 min),
cells treated with IDE and IDE-NLCs showed statistically
significant lower (p < 0.05) values of ROS-positive cells at 30
min (in particular 230 ± 71% for IDE and 195 ± 118% for
IDE-NLCs); at 60 min, IDE-treated cells showed a statistically
nonsignificant lower level of ROS-positive cells (661 ± 331%),
while IDE-NLCs showed a statistically significant lower (p <
0.05) level of ROS-positive cells (541 ± 166%). Four
experimental replicates were performed.
IDE-NLCs administered to ARSACS fibroblasts, exhibiting a
higher basal level of ROS, analogously protected cells,
efficiently counteracting the endogenous ROS levels, similarly
to the action of free IDE (Figure 11, lower panel). In
particular, control and NLC-treated cultures showed similar
ROS-positive cells values at both time points (103 ± 68% for
control at 30 min, 120 ± 52% for NLCs at 30 min, 92 ± 59%
for control at 60 min, and 111 ± 42% for NLCs at 60 min),
while IDE and IDE-NLCs treated cells showed a statistically
significant (p < 0.05) lower level of ROS-positive cells (18 ±
2% for IDE at 30 min, 12 ± 4% for IDE-NLCs at 30 min, 12 ±
6% for IDE at 60 min, and 13 ± 5% for IDE-NLCs at 60 min).
Five experimental replicates were performed. In Figure S5A,
representative flow cytometry plots obtained for human
healthy fibroblasts treated with free IDE, NLCs, and IDE-
Figure 8. (A) WST-1 assay performed on human healthy primary fibroblasts incubated with free IDE, NLCs, and IDE-NLCs. (B) WST-1 assay
performed on human ARSACS patient’s primary fibroblasts incubated with free IDE, NLCs, and IDE-NLCs. Analyses were normalized on
nontreated cells (CTRL); cells were also treated with ethanol (ETOH, used for dissolving free idebenone). *p < 0.05, **p < 0.01, ***p < 0.001.
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NLCs, acquired 30 and 60 min after induction of oxidative
stress by TBH, are reported. Figure S5B displays representative
flow cytometry plots obtained in ARSACS patient’s fibroblasts
treated with free IDE, NLCs, and IDE-NLCs, acquired 30 and
60 min after cell detachment.
■ DISCUSSION
In this work, preparation, characterization, and in vitro testing
of NLCs encapsulating IDE for the treatment of mitochondrial
pathologies have been described. More in detail, the objective
of the present study was to test the significance of a novel IDE-
loaded nanosystem in ARSACS, a condition were oxidative
stress is constitutively high.5 We are proposing a new strategy
for future therapies exploiting biocompatible nanoparticles that
are able to cross the BBB for delivering antioxidants to the
cerebral compartment. The choice of the cargo has led to IDE,
known for its powerful antioxidant effects, by scavenging a
large variety of free radicals and by acting through electron-
donor and H-donor mechanisms.15
NLCs were chosen for their intrinsic ability to load a large
amount of payload, thanks to the liquid lipid component which
forms a flawed structure. The advantages of these kinds of
delivery systems are that they (i) provide prolonged drug
protection, preventing fast renal clearance, (ii) they are a
preferential substrate for facilitated BBB permeability because
of their lipid composition, and (iii) they ensure a sustained
Figure 9. 2D CLSM images of human healthy primary fibroblasts treated for (A) 24, (B) 48, and (C) 72 h with Vybrant DiO-labeled IDE-NLCs
(green). Nuclei (blue) and f-actin (red) were also stained. (D) Flow cytometry quantification of Vybrant DiO-labeled IDE-NLCs positive cells (%)
after 24, 48, and 72 h of incubation at 37 °C. (E) Representative flow cytometry plots obtained at the three time points.
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release, reducing the dose administration frequency. IDE-
NLCs were fabricated by high-temperature homogenization.
Although the technique and material matches are novel, the
work was based on recent studies regarding brain delivery of
SLNs and NLCs. Cetyl palmitate has been chosen for its ability
to provide stability to nanoparticles and to impart small size
and PDI, as compared to other lipids (i.e., beeswax, glyceryl
monostearate, and stearic acid),29 while oleic acid was added as
liquid component. IDE-NLCs showed a suitable size for
nanomedical applications. Indeed, according to the literature,
the best NLC size favoring BBB crossing relies approximately
to 100 nm, thus avoiding fast clearance and improving drug
encapsulation and delivery because of the high surface to
volume ratio.30 IDE-NLCs showed an average hydrodynamic
diameter of 159.3 ± 3.4 nm, resulting small enough to
discourage the obstruction of small capillaries (because of
similar dimensions) and big enough to prevent blood/
lymphatic system uptake.31 Their low PDI (0.224 ± 0.015)
confirmed a good homogeneity in the size and the measured ζ-
potential (−33.5 ± 0.1 mV) makes NLCs highly biocompat-
ible, attaining better colloidal stability.32 TEM images,
although different preparation methods were followed, were
congruent to those reported in other works.24,33 Regarding
stability evaluation of IDE-NLCs, results demonstrated that
Figure 10. 2D CLSM images of human ARSACS patient’s primary fibroblasts treated for (A) 24, (B) 48, and (C) 72 h with Vybrant DiO-labeled
IDE-NLCs (green). Nuclei (blue) and f-actin (red) were also stained. (D) Flow cytometry quantification of Vybrant DiO-labeled IDE-NLCs
positive cells (%) after 24, 48, 72 h of incubation at 37 °C. (E) Representative flow cytometry plots obtained at the three time points.
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IDE-NLCs show good stability at 37 °C, even after one month
and upon dilution in all the considered solvents. Furthermore,
the nanovectors showed a sustained release profile reaching 13
± 2% of IDE release at 72 h, independently from pH and redox
conditions.
IDE-NLCs displayed very low cytotoxic effects, demonstrat-
ing to be biocompatible and nontoxic up to 72 h after
administration in the tested cell lines. An evaluation of
cytotoxicity and cell proliferation was performed on cells
incubated with free drug (IDE), NLCs, and IDE-NLCs, and no
significant cytotoxic effect or reduction in cell proliferation was
observed, except for differentiated SH-SY5Y cells treated with
the highest concentration of IDE at the longest time point. No
significant differences were observed with respect to NLC and
IDE-NLC treatments.
A qualitative assessment of IDE-NLC localization and
internalization rates within cells was performed by confocal
microscopy. The cells, maintaining a physiological cytoskeletal
conformation, presented a cytoplasm rich in nanoparticles,
with a time-dependent internalization (mostly after 48 h of
treatment), mainly localized in the perinuclear area for all the
analyzed cell lines. A quantitative assessment of IDE-NLC
internalization was then conducted by flow cytometry. Also, in
this case, the internalization was mostly time-dependent,
reaching a good amount of nanoparticles in the cells after 72
h in all the cell lines analyzed. Regarding their ability to cross
BBB, an in vitro model resembling the endothelial monolayer
(top, luminal compartment) and the astrocytes (bottom,
abluminal compartment) was exploited, resulting in a TEER of
95 ± 7.5 Ω·cm2. IDE-NLCs were able to permeate the BBB
model and settled the crossing percentage at 19.71% after 72 h.
These preliminary data seem to be very promising and indicate
the capacity of the nanoparticles to cross an in vitro model of
BBB, further corroborating their possible evaluation for future
in vivo studies.
Promising results have been obtained for the evaluation of
IDE-NLC antioxidant efficacy. IDE-NLCs showed an effective
antioxidant protection on human healthy primary skin
fibroblasts. Further studies will be required in order to better
evaluate the efficacy of loaded nanoparticles, considering also
the possible variations in the patient’s responses to increased
oxidative stress.
Because mitochondrial dysfunctions characterize many
neurodegenerative conditions, in the last years new therapeutic
strategies have been envisaged. Mitochondrial targeting could
be a straightforward method for delivering IDE to the site of
interest. In fact, one of the limitations of antioxidants is their
inability to function within the mitochondria.34 It has been
shown that lipophilic cations selectively accumulate within the
mitochondria, because of their negative membrane potential
(130/150 mV in living cells).35 Indeed, they are used to
measure mitochondrial membrane potential (e.g., triphenylme-
thylphosphonium, TPP) as well as to localize the mitochondria
by fluorescence microscopy (e.g., rhodamine). It has been
demonstrated that by conjugating TPP+ salt with the
antioxidant phenolic moiety of vitamin E (MitoVitE), this
was efficiently delivered to the mitochondria. The amount of
MitoVitE specifically uptaken was approximately 80-fold
higher than the endogenous levels of vitamin E.36 Further-
more, it has been shown that MitoVitE was 800-fold more
potent than IDE in cultured fibroblasts derived from patients
affected by FA.37 A similar approach could be applied to IDE,
in order to improve its function once released from NLCs.
■ CONCLUSIONS
To summarize, biocompatible nanoparticles have been
developed as an effective antioxidant delivery system not
only for the treatment of mitochondrial pathologies, yet also as
a novel therapeutic approach for ARSACS and, more in
Figure 11. Upper panel: flow cytometry quantification of CellRox Green in human healthy primary fibroblasts treated with free IDE, NLCs, and
IDE-NLCs for 72 h, acquired 30 min (on the left) and 60 min (on the right) after induction of oxidative stress by TBH; lower panel: flow
cytometry quantification of CellRox Green in ARSACS patient’s primary fibroblasts treated with free IDE, NLCs, and IDE-NLCs for 72 h, acquired
30 min (on the left) and 60 min (on the right) after cell detachment. *p < 0.05.
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general, for neurodegeneration. In order to make these
nanovectors applicable for the treatment of mitochondrial
dysfunctions characterizing many NDs, future IDE-NLCs
could be functionalized with a signal peptide, allowing their
attachment to any mitochondrial subunit and leading to their
targeted import.
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